Cargando…
Translational Science by Public Biotechnology Companies in the IPO“Class of 2000”: The Impact of Technological Maturity
The biotechnology industry plays a central role in the translation of nascent biomedical science into both products that offer material health benefits and creating capital growth. This study examines the relationship between the maturity of technologies in a characteristic life cycle and value crea...
Autores principales: | McNamee, Laura, Ledley, Fred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864935/ https://www.ncbi.nlm.nih.gov/pubmed/24358154 http://dx.doi.org/10.1371/journal.pone.0082195 |
Ejemplares similares
-
Modeling timelines for translational science in cancer; the impact of technological maturation
por: McNamee, Laura M., et al.
Publicado: (2017) -
Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017) -
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
por: Beierlein, Jennifer M., et al.
Publicado: (2017) -
Comparing long-term value creation after biotech and non-biotech IPOs, 1997–2016
por: Cleary, Ekaterina Galkina, et al.
Publicado: (2021) -
Latent class analysis of IPOs in the Nordics
por: Bask, Mikael, et al.
Publicado: (2021)